Novo, United Labs' Triple Agonist Shows 19.7% Weight Loss in Phase II

Novo Nordisk and China's United Laboratories have announced positive Phase II results for their triple agonist, UBT251, in a Chinese population with overweight or obesity. The study evaluated weekly subcutaneous injections of UBT251 (2mg, 4mg, 6mg) against a placebo. After 24 weeks of treatment, the highest dose group achieved a mean weight reduction of 19.7% (17.5 kg) from baseline, compared to a 2.0% reduction in the placebo group. The candidate also showed statistically significant improvements in key secondary metabolic parameters.

UBT251, a long-acting GLP-1/GIP/GCGR triple agonist developed by United Labs' subsidiary Federal Biotechnology, was licensed to Novo for overseas markets in March 2025. The drug was well-tolerated, with the most common adverse events being mild-to-moderate gastrointestinal side effects typical of incretin-based therapies. Based on these results, United Labs plans to initiate a Phase III trial in China, while Novo is progressing a global Phase Ib/IIa study and planning a Phase II trial for type 2 diabetes.

According to PharmCube's NextBiopharm® database, UBT251 ranks third globally in terms of development among GLP-1/GIP/GCGR triple agonists. Click here to request a free trial for NextBiopharm®.

Daily News
Bio-Thera to Transfer CVD Drug to Lepu Pharma for RMB 450m
2026-04-15
J&J Reports 9.9% Q1'26 Revenue Growth, Raises Full-Year Guidance
2026-04-15
Regeneron, Telix Shake on Next-Gen Radiopharmaceuticals
2026-04-14
Revolution Med's Pan-RAS Inhibitor Succeeds in Pivotal Phase III Trial
2026-04-14
Gilead Exercises Option to License Kymera's First-in-Class CDK2 Degrader
2026-04-13
Latest Report
Global Drug Progress Report during January 2026
Details